Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
standard chemotherapy-Hoffmann-La Roche-metastatic rhabdomyosarcoma-metastatic non-rhabdomyosarcoma soft tissue sarcoma
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This chemotherapy regimen refers to the specific multi-agent backbone used as the standard-of-care control arm in the Phase II BERNIE trial (NCT00702234), sponsored by Hoffmann-La Roche. The regimen was designed for pediatric and adolescent patients with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). It consists of an intensive induction phase followed by a maintenance phase. Induction therapy involves either the IVADo regimen (ifosfamide, vincristine, dactinomycin, and doxorubicin) or the IVA regimen (ifosfamide, vincristine, and dactinomycin). This is followed by a maintenance phase consisting of vinorelbine and cyclophosphamide. The combination targets cancer cells through multiple cytotoxic pathways, including DNA cross-linking, microtubule disruption, and inhibition of DNA replication and transcription.
- Other names
- IVADoIVAVinorelbine/Cyclophosphamide maintenanceStandard chemotherapy (BERNIE trial)
02
Targets
DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on standard chemotherapy-Hoffmann-La Roche-metastatic rhabdomyosarcoma-metastatic non-rhabdomyosarcoma soft tissue sarcoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on standard chemotherapy-Hoffmann-La Roche-metastatic rhabdomyosarcoma-metastatic non-rhabdomyosarcoma soft tissue sarcoma.